News

Fulvestrant Adds Punch to Anastrozole for HR+ Breast Cancer

Publish date: December 28, 2011

 

FROM THE SAN ANTONIO BREAST CANCER SYMPOSIUM

Dr. Mehta disclosed receiving grant and research support from AstraZeneca.

Pages

Recommended Reading

Factors Predict Contralateral Breast Cancer Risk in BRCA Carriers
MDedge Hematology and Oncology
Breast Cancer Linked to Benign Thyroid Disease
MDedge Hematology and Oncology
Meta-Analysis: Pregnancy-Associated Breast Cancer Fares Poorly
MDedge Hematology and Oncology
Recent Diabetes Increases Breast Cancer Risk
MDedge Hematology and Oncology
Acupuncture Flops as Relief for Muscle Pain From Aromatase Inhibitors
MDedge Hematology and Oncology
Oncotype DX Cost Effective, Challenges Breast Cancer Practice
MDedge Hematology and Oncology
Vitamin D Deficiency/Breast Cancer Link Questioned
MDedge Hematology and Oncology
Metastatic Work-Up Not Needed for All N2/N3 Breast Cancers
MDedge Hematology and Oncology
T-DM1 Supports QOL in HER2+ Metastatic Breast Cancer
MDedge Hematology and Oncology
Doctors, Patients Disconnected on Aromatase Inhibitor Compliance
MDedge Hematology and Oncology